Alkem Labs — Long-Term Growth Outlook Stays Intact: HDFC Securities

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy. .HDFC Securities Retail Research.Alkem Laboratories Ltd.’s chronic business continues to grow better than market growth rate, leading to improvement in its market share and ranking in therapy segments of central nervous system, anti-diabetic, cardiology and dermatology. International business mainly led by U.S., delivered a healthy performance on the back of new product launches and market share gains in the existing products. Alkem Labs looks to outperform in the chronic segment on the back of-new product launches including in-licensed products,improved sales force productivity andby building strong brands. Alkem Labs has filed a total of 169 abbreviated new drug applications and two new drug applications with the U.S. Food and Drug Administration and has received approvals for 129 ANDAs (including 14 tentative approvals) and two NDAs as on Dec-2022. It has current good manufacturing practice compliant manufacturing facilities and own front end to distribute and market its products. We expect 11.3% compound annual growth rate in revenue led by 11.5% growth in India business and 11% growth in U.S. business over FY23-25E. Higher contribution from chronic portfolio, improving medical representative productivity, falling raw material costs and rising revenue from U.S. could lead to margin expansion of 250 bps over the next two years. Healthy revenue and steady margin of around 17-18% could lead to strong 21% CAGR in profit after tax over the same period..Click on the attachment to read the full report:.NRB Bearings - Gearing Up For The ‘Next Normal’: HDFC Securities.DISCLAIMERThis report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Alkem Labs — Long-Term Growth Outlook Stays Intact: HDFC Securities

Alkem Labs’ chronic business continues to grow better than market growth rate, leading to improvement in its market share.

Choose a plan